# Sequential Treatment Strategy for Metastatic Colorectal Cancer

> **NCT01878422** · PHASE3 · COMPLETED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 376 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Arm A: FOLFIRI or FOLFOX + Bevacizumab
- **DRUG:** Arm B: FOLFIRI or FOLFOX
- **DRUG:** Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
- **DRUG:** Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB

## Key facts

- **NCT ID:** NCT01878422
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2014-03
- **Final completion:** 2016-06-11
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01878422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01878422, "Sequential Treatment Strategy for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01878422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*